Tesaro gets its PD-1 reg­is­tra­tion study start­ed, hunt­ing ac­cel­er­at­ed OK; Ul­tragenyx hus­tles in­to PhI­II

→ Tesaro $TSRO has launched a reg­is­tra­tion study for its PD-1 drug TSR-042, which was de­vel­oped in a col­lab­o­ra­tion with Anap­tys­Bio. The biotech — which is gun­ning for an ac­cel­er­at­ed ap­proval — is plan­ning to start a se­ries of com­bo ef­forts that match the check­point with the new­ly ap­proved Ze­ju­la, TSR-022, an an­ti-TIM-3 an­ti­body, and TSR-033, and an­ti-LAG-3 an­ti­body.

→ No­va­to, CA-based Ul­tragenyx $RARE launched a Phase III study of UX007 for the treat­ment of Glu­cose Trans­porter Type 1 De­fi­cien­cy Syn­drome (Glut1 DS) pa­tients ex­pe­ri­enc­ing dis­abling parox­ys­mal move­ment dis­or­ders.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.